Last reviewed · How we verify
Phase 3B: Clozapine or another SGAs
Clozapine and other second-generation antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and improve mood regulation.
Clozapine and other second-generation antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and improve mood regulation. Used for Schizophrenia, Treatment-resistant schizophrenia, Bipolar disorder.
At a glance
| Generic name | Phase 3B: Clozapine or another SGAs |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Second-generation antipsychotic (atypical antipsychotic) |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Second-generation antipsychotics (SGAs) like clozapine antagonize dopamine D2 receptors and serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical pathways associated with psychosis. Clozapine additionally has activity at multiple other receptors including muscarinic, histaminergic, and adrenergic receptors, which contribute to its efficacy in treatment-resistant schizophrenia and its side effect profile.
Approved indications
- Schizophrenia
- Treatment-resistant schizophrenia
- Bipolar disorder
- Psychotic disorders
Common side effects
- Agranulocytosis
- Weight gain
- Sedation
- Orthostatic hypotension
- Tachycardia
- Metabolic syndrome
- Seizures
- Myocarditis
Key clinical trials
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |